Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens39

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens26

Views

Views
February 20253
March 202513
April 20253
May 20250
June 20251
July 20256
August 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore13
United States5
United Kingdom2
Mexico2
Brazil2
Colombia1
Spain1
 

Top cities views

Views
Anderson1
Bogotá1
Caruaru1
Council Bluffs1
Porto Alegre1
Puerto Vallarta1
Texcoco1